Abstract Background: It has been suggested that overtreatment of infants with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency might affect their growth and final height. Objective: To assess the axiological parameters of infants with CAH due to 21-hydroxylase deficiency from their first presentation in neonatal period and during infancy, in an attempt to decide the optimum doses of glucocorticoid, mineralocorticoid and salt therapy that can achieve androgen suppression, prevent life-threatening salt-wasting crises, and allow normal growth velocity for age. Materials and methods: Retrospective study conducted in the Diabetes Endocrine and Metabolism Pediatric Unit at Children's Hospital, Cairo University included baseline and follow-up data of 28 infants with 21-hydroxylase deficiency. Results: Median age at presentation was 34 days. Lower doses of hydrocortisone (<20 mg/m 2 / day) were associated with better growth, not reaching a statistical significance. Delta change in length standard deviation score (SDS) was significantly higher in males (p = 0.01). Delta change in length and weight SDS of cases with mean basal length SDS below À2 were significantly higher than those with mean basal length SDS above À2 (p = 0.02 and 0.04 respectively). No correlations
Introduction
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder due most commonly, to deficiency of 21-hydroxylase (21-OH) enzyme action that typically reduces cortisol and aldosterone secretion while simultaneously increasing androgen production. 1 Growth is considered a key concern in the management of congenital adrenal hyperplasia (CAH), as infants often fail to reach their target height. Treatment of CAH is based on the administration of glucocorticoid and mineralocorticoid, which decrease ACTH-stimulated excess of adrenal androgen. Higher doses of hydrocortisone may be needed to achieve satisfactory androgen suppression, with subsequent hypercortisolism. 2, 3 The combination of hyperandrogenism and hypercortisolism most likely explains the short adult stature frequently observed in treated children with CAH. 4 Whether this decreased height potential is caused by inadequate suppression of adrenal androgens, excess steroid treatment or the salt wasting state itself is a matter of debate. 5 Current evidence suggests that infancy and peripubertal periods are the time periods when height outcome is most sensitive to glucocorticoid dose. 6, 7 Individualized treatment approaches have been suggested to prevent growth failure. 8 Monitoring of treatment during these critical periods is largely based on the assessment of a certain biochemical investigation with growth velocity and skeletal maturation. The growth velocity and skeletal maturation are the most accurate predictors of long-term outcome of somatic growth. 9 In this study we aimed to assess the axiological parameters of infants with congenital adrenal hyperplasia from their first presentation in the neonatal period and during infancy, in an attempt to decide the optimum doses of glucocorticoid, mineralocorticoid and salt therapy that can achieve androgen suppression, prevent life-threatening salt-wasting crises, and allow normal growth velocity for age.
Subjects and methods
This was a retrospective study that included 28 infants {21 females (46, xx), and 7 males (46, xy)}. The infants were diagnosed as congenital adrenal hyperplasia and were followed-up regularly at The Diabetes Endocrine and Metabolism Pediatric Unit (DEMPU), Children's Hospital of the Cairo University. The study protocol was approved by the University's Research Ethics Committee and was conducted in accordance with the University's bylaws for human research.
The records of all infants and the baseline and data of follow-up visits were reviewed with emphasis on the age at presentation, sex of rearing, presenting complaint, salt wasting symptoms and signs, parental consanguinity, family history of CAH or any abortion or prenatal death. The number of salt wasting crises and number of admissions since start of therapy for each patient were also recorded.
All anthropometric data including length, weight at baseline and at follow-up visits were reviewed. The supine length was measured by using a Harpenden infanotometer and the weight was measured by using an electronic digital scale. Measurements were taken and recorded every 3 months and the Growth vision computer software provided by Novo Nordisk was employed to assess length standard deviation score (SDS) and weight SDS to assess linear growth and weight gain for adjustment of the daily hydrocortisone dose.
According to the protocol adopted at our unit (DEMPU), all infants were treated with daily SC/IM hydrocortisone therapy calculated in mg/m 2 /day and given in two equally divided doses till the age of 9 months, then on oral hydrocortisone (locally manufactured Micort tablets, 10 mg/tab) with the total daily dose divided three times daily. They were also given daily oral fludrocortisone at a dose of 0.05-0.15 mg and advised daily salt therapy. Hydrocortisone doses were adjusted so that 17OH progesterone done every 3 months reaches target level of biochemical control (5-10 ng/ml, 15.2-30.3 nmol/L), and salt wasting crises are prevented. Hydrocortisone doses were doubled with intercurrent illnesses or surgery to be returned to original dose after recovery after recovery.
Statistical analysis
For statistical analysis the mean values of the daily hydrocortisone and fludrocortisone doses were calculated for the whole period of the follow up included in the study. Data management and analysis were performed using SPSS for windows, version 11.0.0. The numerical data were statistically presented in terms of range, mean, standard deviation, median and interquartile range (IQR). Categorical data were summarized as percentages. Comparisons between numerical variables within groups at two different time points were done by Student's paired t-test for parametric data or Wilcoxon Signed Rank test for non-parametric data. Comparisons between numerical variables of two groups were done by Student's unpaired t-test for parametric data or Mann-Whitney Rank Sum test for non-parametric data. Correlations were tested by Pearson co-efficiency for parametric variables and Spearman's rank correlation test for non-parametric variables. 10 All p-values are two sided and considered significant when p-values were less than 0.05. Table 1 illustrates the general characteristics and growth parameters during the studied period. The mean dose of hydrocortisone therapy was 20.2 ± 6.1 mg/m 2 /day (range: 8.6-36 mg/m 2 /day), and for fludrocortisone therapy the mean dose was 24.6 ± 8.8 lg/m 2 /day (range: from 11.5 to 41.0 lg/ m 2 /day). Mean length SDS at the end point was higher, with a delta change 0.3 ± 1.5 (mean ± SD), but not reaching a statistical significance (p = 0.1). The mean weight SDS showed an insignificant improvement from À1.7 ± 1.5 SDS at the start to À1.6 ± 1.1 SDS by the end of the studied period (p = 0.4) with no detectable increase in weight in 7 infants (25%) during the studied period.
Results
Salt losing symptoms and signs were the most common presentation followed by ambiguous genitalia. The median age at presentation was 34 days (range 7-180 days). Genital ambiguity was overlooked in 10/21 (47.6%) females with incorrect male gender assignment and delay in diagnosis. Delay in diagnosis was also found in 5/7 (71.4%) males who were misdiagnosed as sepsis, gastroenteritis and other conditions, with a delay in diagnosis to up to 180 days (6 months). Parental consanguinity was found in 60.7%, and positive family history of similar condition was found in 39.3% of subjects.
Fourteen infants (50%) were controlled on a mean hydrocortisone dose <20 mg/m 2 /day, while the other 14 infants (50%) needed a mean dose P20 mg/m 2 /day. The length and weight SDS of both groups showed statistically insignificant changes from baseline to the end of the follow up period. However, those on low dose showed improvement in both linear and ponderal growths although not reaching a statistical significance. Salt-receiving (n = 18) and non salt-receiving infants (n = 10) showed insignificant changes in their length SDS (p = 0.6, 0.08 respectively), but non salt-receiving infants (n = 10) showed a significant increase in their weight SDS (p = 0.048), (Table 2) .
Males had a significant increase in their length and weight SDS on steroid therapy (p = 0.001, 0.04, respectively) while females showed insignificant changes. The length and weight SDS of infants with a basal mean Ht SDS P À2 (n = 11) showed insignificant changes from baseline measurements to the end of the follow up period (p = 0.4 and 0.2 respectively). While, the length SDS of cases with basal mean Ht SDS below À2 (n = 17) showed a significant increase at the end of the follow up period (p = 0.03), but the weight SDS showed an insignificant decrease (p = 0.1), ( Table 2) .
The delta length SDS and delta weight SDS, growth velocity and growth velocity SDS showed insignificant differences in relation to hydrocortisone dosing or salt supplementation (Table 3). While the delta change in length SDS was significantly higher in males when compared to females (p = 0.01). The delta change in weight SDS, growth velocity and growth velocity SDS were comparable between both sexes (p = 0.2, 0.1, and 0.09 respectively). The delta change in length and weight SDS were significantly higher in infants with basal mean Ht SDS below À2 compared to those with basal mean Ht SDS above À2 (p = 0.02 and 0.04 respectively) ( Table 3) .
A significant proportionate correlation was found between D length-SDS and D weight-SDS (r = 0.5, p = 0.006), as well as growth velocity (r = 0.7, p less than 0.001). A significant proportionate correlation was also found between D weight-SDS and duration of follow-up (r = 0.5, p = 0.04). No significant correlation was found between either D length-SDS or D weight-SDS and hydrocortisone or fluodrocortisone doses. Other tested correlations were not statistically significant (Table 4) .
Discussion
To our knowledge, there are few previous reports of growth parameters in infants with 21-OHD [11] [12] [13] . It is not clear which Table 1 General characteristics, basal and final anthropometric data of the studied cases (n = 28).
General characteristics of the studied cases (n = 28) factors contribute to growth impairment in CAH. Previous studies investigated associations with clinical phenotype, age at start of treatment, hormonal control, and glucocorticoids dosage. [14] [15] [16] [17] [18] It was suggested that the high hydrocortisone doses used during infancy and early childhood, critical periods of rapid growth, lead to growth suppression and may lead to an irreversible loss of adult length. 19, 20 In this retrospective study we have carried out a cross sectional periodic evaluation of a longitudinal follow up, focusing on the effect of the dose of hydrocortisone on the growth rate of 28 children with the salt losing form of congenital adrenal hyperplasia due to 21 hydroxylase deficiency. We analyzed these parameters in relation to the dose of hydrocortisone, fludrocortisone, salt supplementation, age at presentation and gender. To normalize data, length, weight, delta change and growth velocity were analyzed in terms of standard deviation scores (SDSs).
Regarding sex preponderance, this study revealed a female to male ratio of 3:1. This is similar to previous reports in which the majority of cases were females. 21, 22 However, because the gene for this disorder is autosomally recessive, it occurs equally in males and females. This female preponderance can be explained by the fact that males are significantly underdiagnosed and that some of the affected males die without a correct diagnosis as they present only with salt losing crisis and with no genital ambiguity that arouses suspicion of parents or physicians. The median age at presentation was 34 days (range 7-180 days). Genital ambiguity was overlooked in 10/21 (47.6%) females with incorrect male gender assignment and delay in diagnosis. Delay in diagnosis was also found in 5/7 (71.4%) males who were misdiagnosed as sepsis, gastroenteritis and other conditions, with a delay in diagnosis to up to 180 days (6 months). Survival of those infants to that age inspite of the missed diagnosis can be explained by their receiving repeated fluid therapy and steroids empirically for other illnesses. Parental consanguinity was found in 60.7%. Analogous data have been reported by Bhanji and colleagues who found parental consanguinity in 52% of cases, 24 while this percent decreased to 33% in the study of Al-Maghribi. 25 The high rate of consanguinity in the Egyptian population might be responsible for the high incidence of CAH and necessitates genetic counseling for affected families. Positive family history of similar condition was found in 39.3% of subjects. This almost agreed with Bhanji and collegues who reported siblings with a similar condition in 30% of their cases. 24 However, we noted that the presence of a similar condition did not help in early diagnosis, as 6 out of 11 (54.5%) with a positive family history remained unrecognized within the 1st month of life.
Salt losing symptoms and signs were the most common presentation followed by ambiguous genitalia, with unrecognized ambiguity and incorrect gender assignment in 10/21 (47.6%) females. This is different from the observations of Torok et al. 22 and Al-Maghribi, 25 who reported genital ambiguity as the most common presentation followed by salt losing manifestations.
All of the infants received hydrocortisone therapy in a mean dose of 20. On revising the growth parameters among our case series, we found that the mean length and weight-SDS were negative before and remained so after therapy with an insignificant increase. A catch up effect was observed during the studied period as the delta length SDS and delta weight SDS reached positive values. The mean growth velocity of infants under treatment was 13.643 ± 4.696 but growth velocity-SDS was still negative (À0.154 ± 1.605). Six infants (21.4%) length did not increase during the studied period, all of them were girls with 5 on salt supplementation and 4 on hydrocortisone more than 20 mg/m 2 /24 h.
The mean length SDS in our study was much lower than that reported by de Almeida and associates; 26 and Volkl et al. 27 but slightly lower than that reported by Aycan and colleagues. 28 This lower length SDS of our study population may be related to bad compliance and poor control with consequent increased steroid dosage. Other factors such as nutritional status, inter-current illnesses, and the different genetic growth potentials could contribute.
No correlations were found between D Ht-SDS, D Wt-SDS or growth velocity and glucocrticoid dosing. This was in line with Manoli et al. 21 who found no correlation between hydrocortisone dosage and weight SDS. But contradicts Jaaskelainen & Voutilainen, 29 who reported a significant negative correlation between the mean daily glucocorticoid dose and height velocity in the first year of life. However, our cases with hydrocortisone dose less than20 mg/m 2 /24 h showed some improvement in their length SDS and weight SDS over the studied period although not reaching a statistical significance; which means that this group of infants showed an improvement in their length SDS on treatment.
On the other hand, cases with hydrocortisone dose more than 20 mg/m 2 /24 h showed minimal changes in length and weight SDS at the end of the follow up period. In addition, the delta change in weight, length SDS, growth velocity, and growth velocity SDS of cases with low dose were higher when compared to cases with higher doses but not reaching a statistical significance. Two out of 14 (14.3%) cases on low cortisone dose had poor growth rate versus 4/14 (28.6%) of the high cortisone dose group (p = 0.6). These findings agree with Stikkelbroeck et al. who reported that glucocorticoid dose has growth-suppressing effects during the age interval of 6 months to 1 year. 30 Speiser & White 31 stated that salt intake may add some adrenal suppression but our results did not confirm this finding. We found that the Ht-SDS showed statistically insignificant changes from baseline to the end of the follow up period in cases with or without salt supplementation. However, cases without salt supplementation showed a significant increase in their weight SDS over time. The delta length SDS and delta weight SDS, growth velocity and growth velocity SDS showed insignificant differences in relation to salt supplementation.
Males had a significant increase in their length and weight-SDS after therapy and the delta change in length-SDS was significantly higher in males when compared to females. Our results revealed that those who were initially shorter acquired significantly more length by the end of the period of follow up compared to infants who were not pathologically short. Also, the D length-SDS and D weight-SDS were significantly higher in the initially shorter group. We suggest that regardless of the glucocorticoid dose, those who were initially pathologically shorter gained a significantly higher (better) length SDS compared to those who were not pathologically short. Growth velocity and growth velocity SDS were comparable between both groups although GV and GVSDS were higher in the first group but the difference did not reach a statistical significance.
The present study had some limitations being an observational retrospective study. Also, it is to be mentioned that glucocorticoid and fludrocortisone doses were collected in detail, based on patient records (prescribed doses), but no systematic information was available about compliance or about the frequency of temporary overdosing with intercurrent illnesses, and assessment of nutritional status was not available. 
Conclusions
In conclusion, infants with salt wasting CAH had poor linear growth and gain of weight during infancy, which was related neither to the age at diagnosis and start of therapy, nor to the doses of glucocorticoids, fludrocortisones, or saline replacement therapy. More favorable growth catch up was found in male infants, and in those pathologically short at presentation and start of therapy. Lower doses of hydrocortisone (<20 mg/m 2 /day), compared to higher doses, were also associated with better growth, but not reaching a statistical significance. Further prospective studies with a larger number of cases and with inclusion of intercurrent illnesses and nutritional status in infants with CAH are warranted.
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